The Unified Patent Court has ruled that Siemens Healthineers infringed Hologic’s European Patent EP 2 352 431 with its Mammomat B.brilliant mammography system.
The June 10 decision came from the UPC’s Düsseldorf Local Division in proceedings involving Hologic and Siemens Healthineers entities in Germany, the Netherlands, and France.
Hologic said the court imposed an injunction covering Mammomat B.brilliant systems across Germany, France, and the Netherlands. The order prohibits Siemens from making, offering, placing on the market, using, importing, or storing the affected systems for those purposes in those countries.
Recall and destruction obligations are also part of the ruling, according to Hologic. The company said Siemens must recall and destroy affected systems in the covered markets and refund customers for the purchase price and related logistics costs.
The patent concerns control of X-ray focal-spot characteristics for tomosynthesis and mammography imaging. Hologic described the protected technology as part of its Focusing Technology on the Envision platform.
Mammomat B.brilliant is Siemens Healthineers’ digital mammography platform for 2D and 3D breast imaging. The disputed technology concerns the system’s focal-spot approach during breast tomosynthesis.
Hologic said retroactive and future damages and costs will be determined by the court. Siemens Healthineers may still appeal or seek other procedural remedies under UPC rules.
Companies:Hologic, Siemens Healthineers
Sources
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
